<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540292</url>
  </required_header>
  <id_info>
    <org_study_id>TJT1123</org_study_id>
    <nct_id>NCT01540292</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders</brief_title>
  <official_title>Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to assess safety and efficacy of allogeneic Mesenchymal stem Cell (MSC) in&#xD;
      Crohn's disease refractory or intolerant to conventional therapies. Twenty patients with&#xD;
      active refractory Crohn's disease defined by a Crohn's Disease Activity Index (CDAI) &gt; 220&#xD;
      despite conventional treatment will be included over 4 years in this phase I-II trial. This&#xD;
      will be a pilot open label trial. Patients will be treated with 2 successive injections of&#xD;
      allogeneic MSC at baseline and 4 weeks later. Patients will be followed up at weeks 2, 4, 8&#xD;
      and 12.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Collection and expansion of MSC Bone marrow collection and MSC expansion cultures will&#xD;
           be carried out at the Laboratory of Cell and Gene Therapy (LTCG) at the University of&#xD;
           Liège. Bone marrow (50 ml) will be collected from unrelated donors under local&#xD;
           anesthesia, mononuclear cells will be isolated, and cultured for a total of about 4&#xD;
           weeks. After a sufficient number of passages, the cells will be harvested, washed and&#xD;
           frozen.&#xD;
&#xD;
        2. MSC injections MSC will be thawed and diluted at the Laboratory of Cell and Gene Therapy&#xD;
           (LTCG), transported to the hospital ward and injected intravenously within 1 hour of&#xD;
           thawing through a central catheter (when available) or a good peripheral vein. A dose of&#xD;
           1.5 - 2.0 x 106/kg recipient MSC should be ideally administered at each infusion. MSC&#xD;
           will be infused even if the number of post-thaw cells is lower than that. Patients with&#xD;
           Crohn's disease will receive two injections of allogenic MSC 4 weeks apart (week 0 and&#xD;
           4).&#xD;
&#xD;
        3. Patients Follow up&#xD;
&#xD;
      3.1. Quality controls of MSC products Quality controls of MSC product will include&#xD;
      microscopy, nucleated cell count and differential, cell viability testing, microbiology&#xD;
      testing (including standard virology, bacterial culture and detection of mycoplasmal enzymes&#xD;
      by bioluminescence, endotoxin testing, karyotype and FACS analysis (cells must be positive&#xD;
      for :CD90 &gt; 70%,CD105 &gt; 70 %,CD73 &gt; 70 %; and negative for :CD14 &lt; 5%,CD34 &lt; 5%, CD45 &lt; 5%,&#xD;
      CD3 &lt; 1%).&#xD;
&#xD;
      3.2. Toxicities of cell infusions: Potential toxicities associated with MSC infusions will be&#xD;
      carefully monitored per the institution's standards and documented on the infusion report&#xD;
      and/or the SAE report form. No dosage modifications are scheduled. In case of severe reaction&#xD;
      to the first MSC infusion, the second infusion will not be performed.&#xD;
&#xD;
      3.3. Clinical data The following parameters will be followed at baseline as well as at week&#xD;
      2, 4, 8 and 12 : CDAI level, CRP levels, fecal calprotectin levels. In addition, duration of&#xD;
      hospitalization, infections, any other serious complication, and eath and survival will be&#xD;
      recorded.&#xD;
&#xD;
      3.4. Immunologic data: Immune function in the patient will be monitored at baseline and&#xD;
      appropriate intervals: nucleated cell count and differential; FACS analysis with&#xD;
      determination of the % cells (on total WBC) with the markers :CD3+, CD4+, CD8+, CD19+,&#xD;
      CD45RA+, CD45RO+, CD56+, CD3+CD4+, CD3+CD8+; CD3+CD56+; CD4+CD45RA+, CD4+CD45RO+; CD3-CD56+;&#xD;
      regulatory T-cell (Treg) levels; immunoglobulin levels, Vβ repertoire of T lymphocytes; TRECs&#xD;
      quantification in T lymphocytes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">February 1, 2013</start_date>
  <completion_date type="Actual">December 31, 2015</completion_date>
  <primary_completion_date type="Actual">December 31, 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>at week 8</time_frame>
    <description>To assess clinical response rate defined by a 100 points decrease in Crohn's Disease Activity Index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>at week 2, 4, 8 and 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission</measure>
    <time_frame>at week 2, 4, 8 and 12.</time_frame>
    <description>Remission, defined by Crohn's Disease Activity Index &lt;150</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crohn's Disease Activity Index Level</measure>
    <time_frame>at week 2, 4, 8 and 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein levels</measure>
    <time_frame>at week 2, 4, 8 and 12.</time_frame>
    <description>C-reactive Protein measured in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calprotectin levels</measure>
    <time_frame>at week 2, 4, 8 and 12.</time_frame>
    <description>Fecal calprotectin measured in stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune modulation investigation</measure>
    <time_frame>at week 12.</time_frame>
    <description>The following parameters will be taken in account.&#xD;
Nucleated cell count and differential on an automated cell counter;&#xD;
FACS analysis with determination of the % cells (on total WBC) with the markers :&#xD;
CD3+, CD4+, CD8+, CD19+, CD45RA+, CD45RO+, CD56+&#xD;
CD3+CD4+, CD3+CD8+; CD3+CD56+;&#xD;
CD4+CD45RA+, CD4+CD45RO+;&#xD;
CD3-CD56+.&#xD;
Regulatory T-cell (Treg) levels;&#xD;
Immunoglobulin levels (baseline and week 12);&#xD;
Vβ repertoire of T lymphocytes (baseline and week 12);&#xD;
TRECs quantification in T lymphocytes (baseline and week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>by week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Crohn's disease (refractory or intolerant to conventional therapies) treated with 2 successive injections of 1.5-2.0 x 10E6 allogenic MSC/kg BW at baseline and 4 weeks later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stem Cells (MSC)</intervention_name>
    <description>MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart</description>
    <arm_group_label>MSC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 75 years old&#xD;
&#xD;
          -  Crohn's disease affecting terminal ileum, colon or both with diagnosis confirmed&#xD;
             according to Lennard Jones criteria&#xD;
&#xD;
          -  Clinically active disease with a CDAI between 220 and 450 and biologically active&#xD;
             disease with a CRP &gt; 5 mg/l and/or fecal calprotectin &gt; 150 microg/g&#xD;
&#xD;
          -  Resistance or intolerance to mesalazine, steroids, purine analogues, methotrexate,&#xD;
             infliximab and adalimumab&#xD;
&#xD;
          -  Adequate venous access (central catheter or good peripheral veins)&#xD;
&#xD;
          -  Willingness to sign the informed consent and enter the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition not fulfilling inclusion criteria&#xD;
&#xD;
          -  Indication for surgery&#xD;
&#xD;
          -  Symptomatic stricture&#xD;
&#xD;
          -  Undrained perianal or intraabdominal abscess&#xD;
&#xD;
          -  Change in mesalazine dosage within the last 4 weeks, change in steroid dosage within&#xD;
             the last two weeks, change in immunosuppressant dosage within the last 3 months, use&#xD;
             of anti-TNF treatment within the last two months&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Uncontrolled infection, arrhythmia or hypertension&#xD;
&#xD;
          -  Terminal organ failure:&#xD;
&#xD;
               -  Renal: anuria, serious fluid overload, GFR &lt; 30 ml/min, dialysis;&#xD;
&#xD;
               -  Pulmonary: DLCO &lt; 35% and/or receiving supplementary continuous oxygen;&#xD;
&#xD;
               -  Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal&#xD;
                  hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding&#xD;
                  esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic&#xD;
                  dysfunction evinced by prolongation of the prothrombin time, ascites related to&#xD;
                  portal hypertension, bacterial or fungal liver abscess, biliary obstruction,&#xD;
                  chronic viral hepatitis with total serum bilirubin &gt; 3 mg/dL, and symptomatic&#xD;
                  biliary disease;&#xD;
&#xD;
               -  Cardiac: Symptomatic coronary artery disease or other cardiac failure requiring&#xD;
                  therapy; ejection fraction &lt; 35%; uncontrolled arrhythmia, uncontrolled&#xD;
                  hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Beguin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edouard Louis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Yves Beguin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Crohn's disease</keyword>
  <keyword>Mesenchymal Stem Cell</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Inflammatory disorders</keyword>
  <keyword>Autoimmune disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

